BIOMAT Database Logo BIOMAT Database Logo

[Urinary phosphate and cyclic adenosine monophosphate response to intravenous administration of synthetic human parathyroid hormone-(1-34) in idiopathic hypoparathyroidism, pseudohypoparathyroidism, pseudopseudohypoparathyroidism and normal subjects]. 1984

T Fukami, and T Fujita, and Y Yoshimoto, and M Fukase, and Y Imai, and K Sakaguchi, and E Ogata, and Y Furukawa, and H Suzuki, and K Takebe

The response to exogenous parathyroid hormone (PTH) with urinary excretion of phosphate and cyclic adenosine monophosphate (cAMP) was tested by the use of synthetic human parathyroid hormone (1-34) [hPTH-(1-34)] on 59 patients with hypocalcemia and normal or high serum inorganic phosphorus and normal renal function without a history of parathyroidectomy for differentiation between idiopathic hypoparathyroidism (IHP), pseudohypoparathyroidism (PHP) and related diseases along with 18 normal subjects. A positive phosphaturic response to exogenous PTH was defined as the increment of 2 hours phosphate excretion (delta P) of more than 35 mg. A positive urinary cAMP response to exogenous PTH was defined as the increment by more than 1 mumole per one hour (delta cAMP) and the increase of 1 hour excretion by more than 10 times. Increments of 2 hours urinary phosphate excretion in response to hPTH-(1-34) 100 units were 60.5 +/- 7.7 mg (mean +/- SEM) in 27 patients with IHP, 23.5 +/- 5.9 mg in 21 patients with PHP type I and 24.9 +/- 4.0 mg in 17 normal subjects. Increments of 1 hour urinary cAMP excretion in response to hPTH-(1-34) 100 units were 12.0 +/- 1.5 mumole in 27 patients with IHP, 0.33 +/- 0.10 mumole in patients with PHP type I and 23.6 +/- 5.8 mumole in 15 normal subjects. Ratios of 1 hour urinary cAMP excretion were 97 +/- 10 in 27 patients with IHP, 3.6 +/- 0.5 in 21 patients with PHP type I and 54 +/- 14 in 15 normal subjects. Positive phosphaturic and negative urinary cAMP response was encountered in 3 out of 21 patients with PHP type I in response to hPTH-(1-34). This exaggerated phosphaturic response should be considered as due to the influence of treatment with Ca or vitamin D derivatives.

UI MeSH Term Description Entries
D007011 Hypoparathyroidism A condition caused by a deficiency of PARATHYROID HORMONE (or PTH). It is characterized by HYPOCALCEMIA and hyperphosphatemia. Hypocalcemia leads to TETANY. The acquired form is due to removal or injuries to the PARATHYROID GLANDS. The congenital form is due to mutations of genes, such as TBX1; (see DIGEORGE SYNDROME); CASR encoding CALCIUM-SENSING RECEPTOR; or PTH encoding parathyroid hormone. Idiopathic Hypoparathyroidism,Hypoparathyroidism, Idiopathic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010281 Parathyroid Hormone A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates. Natpara,PTH (1-84),PTH(1-34),Parathormone,Parathyrin,Parathyroid Hormone (1-34),Parathyroid Hormone (1-84),Parathyroid Hormone Peptide (1-34),Hormone, Parathyroid
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010710 Phosphates Inorganic salts of phosphoric acid. Inorganic Phosphate,Phosphates, Inorganic,Inorganic Phosphates,Orthophosphate,Phosphate,Phosphate, Inorganic
D011547 Pseudohypoparathyroidism A hereditary syndrome clinically similar to HYPOPARATHYROIDISM. It is characterized by HYPOCALCEMIA; HYPERPHOSPHATEMIA; and associated skeletal development impairment and caused by failure of response to PARATHYROID HORMONE rather than deficiencies. A severe form with resistance to multiple hormones is referred to as Type 1a and is associated with maternal mutant allele of the ALPHA CHAIN OF STIMULATORY G PROTEIN. Albright Hereditary Osteodystrophy,PHPIa,Albright Hereditary Osteodystrophy with Multiple Hormone Resistance,PHD Ib,PHD1b,PHP Ia,Pseudohypoparathyroidism Type 1B,Pseudohypoparathyroidism, Type Ia,Pseudohypoparathyroidism, Type Ib,Hereditary Osteodystrophy, Albright,Osteodystrophy, Albright Hereditary,Pseudohypoparathyroidism Type 1Bs,Pseudohypoparathyroidisms,Pseudohypoparathyroidisms, Type Ia,Pseudohypoparathyroidisms, Type Ib,Type Ia Pseudohypoparathyroidism,Type Ia Pseudohypoparathyroidisms,Type Ib Pseudohypoparathyroidism,Type Ib Pseudohypoparathyroidisms
D011556 Pseudopseudohypoparathyroidism A form of PSEUDOHYPOPARATHYROIDISM characterized by the same features except for the abnormal response to hormones such as PARATHYROID HORMONE. It is associated with paternally inherited mutant alleles of the ALPHA CHAIN OF STIMULATORY G PROTEIN. Albright Hereditary Osteodystrophy without Multiple Hormone Resistance,Pseudo-Pseudohypoparathyroidism,Pseudopseudo-Hypoparathyroidism,Pseudo Pseudohypoparathyroidism,Pseudo-Pseudohypoparathyroidisms,Pseudopseudo Hypoparathyroidism,Pseudopseudo-Hypoparathyroidisms,Pseudopseudohypoparathyroidisms
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D005260 Female Females

Related Publications

T Fukami, and T Fujita, and Y Yoshimoto, and M Fukase, and Y Imai, and K Sakaguchi, and E Ogata, and Y Furukawa, and H Suzuki, and K Takebe
Pseudohypoparathyroidism and idiopathic hypoparathyroidism: relationship between serum calcium and parathyroid hormone levels and urinary cyclic adenosine-3',5'-monophosphate response to parathyroid extract.
June 1978, The Journal of clinical endocrinology and metabolism,
T Fukami, and T Fujita, and Y Yoshimoto, and M Fukase, and Y Imai, and K Sakaguchi, and E Ogata, and Y Furukawa, and H Suzuki, and K Takebe
[Effects of synthetic human parathyroid hormone (1-34) on plasma and urinary adenosine 3',5'-monophosphate and urinary phosphate and calcium in patients with hypoparathyroidism and pseudohypoparathyroidism (author's transl)].
November 1981, Nihon Naibunpi Gakkai zasshi,
T Fukami, and T Fujita, and Y Yoshimoto, and M Fukase, and Y Imai, and K Sakaguchi, and E Ogata, and Y Furukawa, and H Suzuki, and K Takebe
Renal 1,25-dihydroxyvitamin D, phosphaturic, and cyclic-AMP responses to intravenous synthetic human parathyroid hormone-(1-34) administration in normal subjects.
April 1984, Clinical endocrinology,
T Fukami, and T Fujita, and Y Yoshimoto, and M Fukase, and Y Imai, and K Sakaguchi, and E Ogata, and Y Furukawa, and H Suzuki, and K Takebe
Renal response to intravenous phosphate load in idiopathic hypoparathyroidism and pseudohypoparathyroidism.
July 1967, Acta paediatrica Scandinavica,
T Fukami, and T Fujita, and Y Yoshimoto, and M Fukase, and Y Imai, and K Sakaguchi, and E Ogata, and Y Furukawa, and H Suzuki, and K Takebe
Synthetic human parathyroid hormone-(1-34) for the study of pseudohypoparathyroidism.
November 1988, The Journal of clinical endocrinology and metabolism,
T Fukami, and T Fujita, and Y Yoshimoto, and M Fukase, and Y Imai, and K Sakaguchi, and E Ogata, and Y Furukawa, and H Suzuki, and K Takebe
Parathyroid hormone-(1-34) peptide activates cyclic adenosine 3',5'-monophosphate in the human placenta.
March 1991, Experimental physiology,
T Fukami, and T Fujita, and Y Yoshimoto, and M Fukase, and Y Imai, and K Sakaguchi, and E Ogata, and Y Furukawa, and H Suzuki, and K Takebe
Plasma cyclic AMP response to intravenous parathyroid hormone in pseudohypoparathyroidism.
March 1991, Acta paediatrica Scandinavica,
T Fukami, and T Fujita, and Y Yoshimoto, and M Fukase, and Y Imai, and K Sakaguchi, and E Ogata, and Y Furukawa, and H Suzuki, and K Takebe
Transient hypoparathyroidism induced by synthetic human parathyroid hormone-(1-34) treatment.
May 1987, The Journal of clinical endocrinology and metabolism,
T Fukami, and T Fujita, and Y Yoshimoto, and M Fukase, and Y Imai, and K Sakaguchi, and E Ogata, and Y Furukawa, and H Suzuki, and K Takebe
The effects of oral furosemide on the response of urinary excretion of cyclic adenosine monophosphate and phosphate to parathyroid extract in normal subjects.
January 1985, Nephron,
T Fukami, and T Fujita, and Y Yoshimoto, and M Fukase, and Y Imai, and K Sakaguchi, and E Ogata, and Y Furukawa, and H Suzuki, and K Takebe
Renal and adrenal adenosine 3',5'-monophosphate production and corticosteroid secretion in response to synthetic chicken parathyroid hormone-(1-34).
August 1989, Endocrinology,
Copied contents to your clipboard!